

## Morfin versus oxikodon

### Referenser:

#### Översikter

1. Goodman & Gilman's **The Pharmacological Basis of Therapeutics**, 12th edition : Laurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann, eds., McGraw-Hill, 2011.
2. Kalso E. **Oxycodone**. J Pain Symptom Manage. 2005 May;29(5 Suppl):S47-56.
3. Drewes AM<sup>1</sup>, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, Riley J, Dahan A. **Differences between opioids: pharmacological, experimental, clinical and economical perspectives**. Br J Clin Pharmacol. 2013 Jan;75(1):60-78. doi: 10.1111/j.1365-2125.2012.04317.x.

#### Systematiska granskningar med avseende på smärtlindring

4. Reid CM, Martin RM, Sterne JA, Davies AN, Hanks GW. **Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials**. Arch Intern Med. 2006 Apr 24;166(8):837-43.
5. King SJ<sup>1</sup>, Reid C, Forbes K, Hanks G. **A systematic review of oxycodone in the management of cancer pain**. Palliat Med. 2011 Jul;25(5):454-70. doi: 10.1177/0269216311401948.
6. Wiffen PJ<sup>1</sup>, Wee B, Moore RA. **Oral morphine for cancer pain**. Cochrane Database Syst Rev. 2013 Jul 22;7:CD003868. doi: 10.1002/14651858.CD003868.pub3.
7. Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS. **Oxycodone for cancer-related pain**. Cochrane Database Syst Rev. 2015 Feb 27;2:CD003870. doi: 10.1002/14651858.CD003870.pub5.
8. Gaskell H<sup>1</sup>, Moore RA, Derry S, Stannard C. **Oxycodone for neuropathic pain and fibromyalgia in adults**. Cochrane Database Syst Rev. 2014 Jun 23;6:CD010692. doi: 10.1002/14651858.CD010692.pub2.

#### Enskilda studier som jämför smärtlindrande effekt av morfin och oxikodon

9. Silvasti M, Rosenberg P, Seppälä T, Svartling N, Pitkänen M. **Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia**. Acta Anaesthesiol Scand. 1998 May;42(5):576-80.
10. Curtis GB, Johnson GH, Clark P, Taylor R, Brown J, O'Callaghan R, Shi M, Lacouture PG. **Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model**. Eur J Clin Pharmacol. 1999 Aug;55(6):425-9.
11. Lenz H, Sandvik L, Qvigstad E, Bjerkelund CE, Raeder J. **A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy**. Anesth Analg. 2009 Oct;109(4):1279-83. doi: 10.1213/ane.0b013e3181b0f0bb.
12. Riley J, Branford R, Droney J, Gretton S, Sato H, Kennett A, Oyeboode C, Thick M, Wells A, Williams J, Welsh K, Ross J. **Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial**. J Pain Symptom Manage. 2015 Feb;49(2):161-72. doi: 10.1016/j.jpainsymman.2014.05.021.

Farmakokinetik

13. Boström E, Hammarlund-Udenaes M, Simonsson US. **Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine.** *Anesthesiology*. 2008 Mar;108(3):495-505. doi: 10.1097/ALN.0b013e318164cf9e.
14. Sadiq MW, Boström E, Keizer R, Björkman S, Hammarlund-Udenaes M. Oxymorphone active uptake at the blood-brain barrier and population modeling of its pharmacokinetic-pharmacodynamic relationship. *J Pharm Sci*. 2013 Sep;102(9):3320-31. doi: 10.1002/jps.23492.
15. Klimas R, Mikus G. **Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide.** *Br J Anaesth*. 2014 Dec;113(6):935-44. doi: 10.1093/bja/aeu186.
16. De Gregori S, Minella CE, De Gregori M, Tinelli C, Ranzani GN, Govoni S, Allegri M, Regazzi M. **Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.** *Ther Drug Monit*. 2014 Jun;36(3):335-44. doi: 10.1097/FTD.000000000000009.

Farmakogenetik

17. Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, Brøsen K, Sindrup SH. **The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.** *Basic Clin Pharmacol Toxicol*. 2009 Apr;104(4):335-44. doi: 10.1111/j.1742-7843.2009.00378.x.
18. Zwisler ST, Enggaard TP, Mikkelsen S, Brøsen K, Sindrup SH. **Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.** *Acta Anaesthesiol Scand*. 2010 Feb;54(2):232-40. doi: 10.1111/j.1399-6576.2009.02104.x.
19. Stamer UM, Zhang L, Book M, Lehmann LE, Stuber F, Musshoff F. **CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.** *PLoS One*. 2013;8(3):e60239. doi: 10.1371/journal.pone.0060239.

Interaktioner:

20. SFINX interaktionstjänst. Janusinfo, Stockholms läns landsting, [www.janusinfo.se/sfinx/interactions](http://www.janusinfo.se/sfinx/interactions) (interaktioner mellan oxikodon och erytromycin/ itrakonazol/ketokonazol/ telaprevir/enzalutamid; läst 2015-11-30:)
21. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA. **The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.** *Br J Pharmacol*. 2010 Jun;160(4):907-18. doi: 10.1111/j.1476-5381.2010.00673.x.
22. Grönlund J<sup>1</sup>, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. **Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.** *Br J Clin Pharmacol*. 2010 Jul;70(1):78-87. doi: 10.1111/j.1365-2125.2010.03653.x.
23. Samer CF<sup>1</sup>, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA. **Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.** *Br J Pharmacol*. 2010 Jun;160(4):919-30. doi: 10.1111/j.1476-5381.2010.00709.x.
24. Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. **Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.** *Br J Clin Pharmacol*. 2010 Jul;70(1):78-87. doi: 10.1111/j.1365-2125.2010.03653.x.
25. Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krähenbühl S. **Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.** *Eur J Clin Pharmacol*. 2011 Jan;67(1):63-71. doi: 10.1007/s00228-010-0893-3.

26. Liukas A, Hagelberg NM, Kuusniemi K, Neuvonen PJ, Olkkola KT. **Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.** J Clin Psychopharmacol. 2011 Jun;31(3):302-8. doi: 10.1097/JCP.0b013e3182189892.
27. Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, Olkkola KT. **Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.** Clin Drug Investig. 2011;31(3):143-53. doi: 10.2165/11539950-000000000-00000.

## Ålder

28. Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Neuvonen M, Neuvonen PJ, Olkkola KT. **Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.** Drugs Aging. 2011 Jan 1;28(1):41-50. doi: 10.2165/11586140-000000000-00000.
29. De Gregori S, Minella CE, De Gregori M, Tinelli C, Ranzani GN, Govoni S, Allegri M, Regazzi M. **Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.** Ther Drug Monit. 2014 Jun;36(3):335-44. doi: 10.1097/FTD.000000000000009.

## Missbrukspotential

30. Wightman R, Perrone J, Portelli I, Nelson L. **Likeability and abuse liability of commonly prescribed opioids.** J Med Toxicol. 2012 Dec;8(4):335-40. doi: 10.1007/s13181-012-0263-x.

## Försäljningstatistik

31. EHälsomyndigheten: apotekens försäljningsstatistik via <https://concise.receptpartner.se/INSIKT/> (avläst i december 2015)

2016-01-05/EV